Monday, February 20, 2023

A previous COVID infection protected against reinfections and severe diseases better than a two-dose m-RNA vaccine, according to a Lancet study

1. A recent Lancet review and meta-analysis titled "Past SARS-CoV-2 infection protection against re-infection:" provides additional insight into natural immunity and vaccine-induced protection a precise survey and meta-examination" has observed that insurance from past contamination and any indicative infection is relatively great for all variations of the Coronavirus causing Covid.

65 studies from 19 countries, including India, were included in the systematic review and meta-analysis. 

2. Pre-Omicron variant infection protection offers The study found that ancestral, alpha, beta, and delta variants protected against reinfection from pre-Omicron variants by approximately 85 percent; which decreased to 79% in ten months.

According to the report, "Protection from previous infection against reinfection from pre-omicron variants was very high and remained high even after 40 weeks."

3.Protection against Omicron variation reinfection

This security was relatively less for "the omicron BA.1 variation and declined more quickly over the long haul than assurance against past variations" the review found.

A pre-Omicron variant infection protected against Omicron BA.1 reinfection at first was 74%, but after 10 months, this protection dropped to 36%.
However, infection with the Omicron variant protected against Omicron reinfection to a greater extent. When the previous infection was pre-omicron, the findings for omicron sublineages generally demonstrated significantly reduced protection. Protection was maintained at a higher level when the previous infection was omicron, but less so for BA.4 and BA.5, indicating that this sublineage has a greater immune escape."

4. Protection from severe diseases The study reveals that, despite offering varying degrees of protection against cross-infection, the Omicron and pre-Omicron variants offer a high degree of protection against severe diseases. The protection level remained higher than 88% even after ten months, and the mean effectiveness of all variants against severe diseases, including hospitalization and death, was found to be greater than 78%. At 40 weeks, the ancestral, alpha, and delta variants' protection against severe disease remained high at 90%, while omicron BA.1's protection against severe disease remained high at 89%.

5. Protection against previous infections comparable to that provided by two-dose mRNA vaccines The researchers have stated that their findings demonstrate that the omicron BA.1 variant offers significantly less protection against re-infection than previous variants, highlighting the variant's high immune escape features. They went on to say, "Our finding that the level of protection against past infection by variant and over time is equivalent to that provided by two-dose mRNA vaccines has important implications for guidance regarding the timing of vaccine doses, including boosters."

6. It is anticipated that Omicron variants will have infected 46% of the world's population by November 14, 2022. Right, Omicron is the predominant coronavirus variant. Nearly 3.8 million people, or 46% of the world's population, had contracted the Omicron variant by November 14, 2022, almost a year after it overtook Delta. For the review and meta analysis, the researchers found 65 studies from 19 countries, including Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, India, Italy, the Netherlands, Nicaragua, Norway, Qatar, South Africa, Sweden, Switzerland, the UK, and the United States.

Catch Daily Highlights In Your Email

* indicates required

Post Top Ad